Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Memgen Announces Addition to Board of Directors
BiotechnologyCompany Update

Memgen Announces Addition to Board of Directors

April 2, 2020 6:00 AM

HOUSTON / ACCESSWIRE / April 2, 2020 / ​Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that Christopher Pagano has joined the company's Board of Directors. "I am delighted to join the board of Memgen at this exciting time in the company's development," noted Mr. Pagano. "Memgen is exploiting leading-edge science to develop novel and effective treatments for cancer patients who currently...

Read more
Mota Raises $1.7 Million in Private Placement
BiotechnologyFinancing

Mota Raises $1.7 Million in Private Placement

April 1, 2020 3:00 AM

VANCOUVER, BC / ACCESSWIRE / April 1, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the "Company") is pleased to announce that it has completed an offering (the "Offering") of 6,142,859 units (each, a "Unit") by way of non-brokered private placement at a price of $0.28 per Unit for gross proceeds of $1,720,000. Each Unit consists of one common share of the Company, and one common share purchase warrant (each, a "Warrant")...

Read more
Angle PLC Announces COVID-19 BUSINESS IMPACT UPDATE
BiotechnologyRegulatory

Angle PLC Announces COVID-19 BUSINESS IMPACT UPDATE

March 31, 2020 2:00 AM

GUILDFORD, SURREY / ACCESSWIRE / March 31, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, provides an update in relation to the impact of the Coronavirus (COVID-19) pandemic on its business. ANGLE's operations and activities in the UK, Canada and the US have all been impacted by the COVID-19 pandemic and resulting Government directives. We take the health, safety and wellbeing of our staff, blood donors and...

Read more
Dyadic Reports 2019 Year End Results and Recent Developments
BiotechnologyEarnings

Dyadic Reports 2019 Year End Results and Recent Developments

March 30, 2020 4:00 PM

New research license agreement with WuXi Biologics, a leading global CDMO Two new fully funded collaborations and one expanded collaboration signed in 2020, including the third fully funded collaboration with a top tier animal health company Six funded research collaborations and one expanded collaboration signed in 2019 Expanded strategic R&D relationships to assist in the development of COVID-19 vaccine and antibodies Expanded internal product...

Read more
ZIVO Bioscience Appoints Industry Veterans To Join Senior Management Team
BiotechnologyCompany UpdateInvestor Relations

ZIVO Bioscience Appoints Industry Veterans To Join Senior Management Team

March 30, 2020 11:20 AM

KEEGO HARBOR, MI / ACCESSWIRE / March 30, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal cultures, is pleased to announce today the addition of Christine O'Neil and Dr. David Lafond to its leadership team. Christine and Dave bring to the organization executive-level experience in the food, supplement, and pet food industry and will...

Read more
Dyadic Announces Nonexclusive Research License with WuXi Biologics
BiotechnologyCompany Update

Dyadic Announces Nonexclusive Research License with WuXi Biologics

March 30, 2020 9:00 AM

JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it has entered into a...

Read more
Mota Ventures Successful Immune Line Launch Signs Up Over 5,500 New Customers in 12 Days
BiotechnologyCompany Update

Mota Ventures Successful Immune Line Launch Signs Up Over 5,500 New Customers in 12 Days

March 27, 2020 4:50 PM

VANCOUVER, BC / ACCESSWIRE / March 27, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the "Company" or "Mota") is pleased to announce that since the launch of its Immune Support product line on March 14, 2020, the Company has acquired over 5,500 new customers seeking natural solutions to help support their family's immune systems. The popularity of the primary product has yielded an average initial order value for immune...

Read more
Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update
BiotechnologyCompany UpdateEarnings

Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update

March 27, 2020 9:00 AM

-Company continues to advance preclinical development of its XCART™ CAR T therapy platform - - Expands XCART resources by adding expertise in cell therapy translational science and CMC - - Cash on hand expected to fund operations through mid-2021 - FRAMINGHAM, MA / ACCESSWIRE / March 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T...

Read more
Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2019 Results
BiotechnologyConference CallEarnings

Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2019 Results

March 26, 2020 4:00 PM

AUSTIN, TX / ACCESSWIRE / March 26, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the fourth quarter and year ended December 31, 2019. The Company will hold a conference call today at 3:30 p.m. CT / 4:30 p.m. ET to discuss its results. Highlights Fourth quarter U.S. OverStitch™ Endoscopic...

Read more
Mota Ventures Moves Forward with Its Acquisition of Spanish CBD Company Sativida
BiotechnologyCompany Update

Mota Ventures Moves Forward with Its Acquisition of Spanish CBD Company Sativida

March 26, 2020 4:00 AM

VANCOUVER, BC / ACCESSWIRE / March 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the "Company" or "Mota") is pleased to announce that further to its January 10, 2020 news release, it has now acquired the intellectual property and trade names of Sativida from Sativida OU (Estonia). The Company will license both back to Sativida OU's subsidiary, VIDA BCN LABS S.L. (collectively with Sativida OU, "Sativida") in exchange for...

Read more
DECN to Add 2nd Covid-19 Test Kit Using Antibody/Antigen Methodology as a Determination Test for Patients Who Previously Tested Positive for Covid-19
BiotechnologyProduct Announcements

DECN to Add 2nd Covid-19 Test Kit Using Antibody/Antigen Methodology as a Determination Test for Patients Who Previously Tested Positive for Covid-19

March 25, 2020 10:15 AM

COMPANY TO AGAIN SEEK FDA EUA FOR ITS CONFIRMATION KIT MAKING DECN THE FIRST TO OFFER TWO TYPES OF COVID-19 TEST KITS, A SCREENING KIT AND A POST SCREEN CONFIRMATION KIT LOS ANGELES, CA / ACCESSWIRE / March 25, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and...

Read more
Molecular Partners Publishes Invitation to Annual General Meeting 2020
BiotechnologyShareholder Meeting

Molecular Partners Publishes Invitation to Annual General Meeting 2020

March 25, 2020 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 25, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today published the invitation to the Annual General Meeting 2020. The Annual General Meeting will be held on Wednesday, April 29, 2020, 2.00 pm CET, at the registered office of the company: Molecular Partners AG, Wagistrasse 14, 5th floor, 8952...

Read more
Apollo Endosurgery, Inc. to Report Fourth Quarter and Full Year 2019 Results on March 26, 2020
BiotechnologyEarnings

Apollo Endosurgery, Inc. to Report Fourth Quarter and Full Year 2019 Results on March 26, 2020

March 24, 2020 4:30 PM

AUSTIN, TX / ACCESSWIRE / March 24, 2020 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq: APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the fourth quarter and full year ended December 31, 2019 on Thursday, March 26, 2020, after the U.S. stock markets close. Apollo will hold a conference call on Thursday,...

Read more
Pieris Pharmaceuticals Provides Update on Servier Collaboration
BiotechnologyCompany Update

Pieris Pharmaceuticals Provides Update on Servier Collaboration

March 23, 2020 4:30 PM

BOSTON, MA / ACCESSWIRE / March 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, today announced an update on its strategic immuno-oncology collaboration with Servier, originally established in 2017. After conducting an extensive portfolio review, Servier has decided to...

Read more
Artelo Biosciences to Present at the Spring Investor Summit on March 25th
BiotechnologyConferences

Artelo Biosciences to Present at the Spring Investor Summit on March 25th

March 23, 2020 9:00 AM

LA JOLLA, CA / ACCESSWIRE / March 23, 2020 / Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that it will be presenting at the 2020 Spring Investor Summit being held on March 25th-26th, featuring over 500 registered executives and investors. Due to the ongoing concerns related to COVID-19, the Spring Investor Summit, which was...

Read more
DECN to Finance 2Q 2020 Roll Out of its GenViro! Covid-19
BiotechnologyFinancingProduct Announcements

DECN to Finance 2Q 2020 Roll Out of its GenViro! Covid-19 "Rapid" Kits Using Non-Dilutive Debt Financing Totaling $13 Million Acquired in Near 0% Rate Environment

March 20, 2020 8:55 AM

COMPANY SEIZES OPPORTUNITY TO GET ITS 60 SECOND GENVIRO! "RAPID" KITS INTO THE MARKET, RECEIVES INITIAL DEBT COMMITMENT FROM PRIVATE FUNDS, PRODUCT UPDATES RESUME NEXT WEEK LOS ANGELES, CA / ACCESSWIRE / March 20, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and...

Read more
Molecular Partners Publishes Audited Financial Results for 2019 and Annual Report 2019
BiotechnologyEarningsInvestor Relations

Molecular Partners Publishes Audited Financial Results for 2019 and Annual Report 2019

March 20, 2020 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 20, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today published its audited Financial Results for 2019 and the company's 2019 Annual Report. The Audited Financial Results for 2019 and the company's 2019 Annual Report are available on the investors section of the company's website. Audited Key...

Read more
Nascent Biotech has Begun In Vitro Studies as a Potential Therapeutic Agent Against COVID-19
BiotechnologyCompany Update

Nascent Biotech has Begun In Vitro Studies as a Potential Therapeutic Agent Against COVID-19

March 19, 2020 9:45 AM

SAN DIEGO, CA / ACCESSWIRE / March 19, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), today announced it has begun research on a possible treatment for patients infected with COVID-19. As previously mentioned in the scientific literature (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) Pritumumab's specific target, cell surface vimentin, is a potential target in the treatment of conditions related to...

Read more
Dyadic Presents New Business Opportunities to Address  COVID-19, Influenza and Continued Scientific and Business Development Progress
BiotechnologyCompany Update

Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress

March 18, 2020 4:15 PM

JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its management participated in...

Read more
Aqualung Therapeutics Advances Its Investigational Monoclonal Antibody into IND-Enabling Studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)
BiotechnologyCompany Update

Aqualung Therapeutics Advances Its Investigational Monoclonal Antibody into IND-Enabling Studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)

March 18, 2020 3:05 PM

COVID-19 and exposure to mechanical ventilation increase unchecked inflammation and ARDS mortality(ARDS) AND VENTILATOR-INDUCED LUNG INJURY (VILI) TUCSON, AZ / ACCESSWIRE / March 18, 2020 / Aqualung Therapeutics Corporation is developing ALT-100, a therapeutic monoclonal antibody, to combat serious unchecked inflammation. The initial application aims to reduce the mortality of Acute Respiratory Distress Syndrome (ARDS) and Ventilator-Induced...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?